GlassScriptPhysician profile
Abhishek Sinha
NPI 1902971567
$7,551.09
in general payments reported to CMS, 2019-2025
29 companies · $1,945 in 2025
The $1,945 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,926 · 2020: $13.80 · 2021: $774 · 2022: $859 · 2023: $986 · 2024: $1,048 · 2025: $1,945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,549 · Consulting Fee: $430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,548.61 |
| Consulting Fee | $430.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $1,919.03 | 2019 | |
| Edwards Lifesciences Corporation | $1,425.90 | 2021-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Novartis Pharmaceuticals Corporation | $1,091.14 | 2021-2025 | |
| Abbott Laboratories | $659.89 | 2020-2024 | Pressurewire, Aveir, Hi-Torque Connect |
| Boston Scientific Corporation | $431.30 | 2022-2025 | Avvigo Guidance System, Rotapro, Opticross |
| Merck Sharp & Dohme LLC | $223.34 | 2021-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $175.40 | 2021-2023 | Farxiga |
| Pfizer INC. | $148.20 | 2021-2025 | |
| Kiniksa Pharmaceuticals, LTD. | $143.63 | 2022-2023 | Arcalyst |
| Abiomed | $140.51 | 2023-2024 | Impella |
| E.R. Squibb & Sons, L.L.C. | $135.09 | 2022-2025 | Eliquis, Camzyos |
| Medtronic, INC. | $133.96 | 2024-2025 | Corevalve Evolut R, Selectsecure |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.49 | 2023-2025 | Jardiance |
| Amgen INC. | $113.90 | 2021-2024 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $96.94 | 2019-2025 | Lifevest |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $88.29 | 2023 | Barostim Neo System |
| Cardiva Medical, INC. | $66.54 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| W. L. Gore & Associates, INC. | $52.06 | 2024-2025 | Gore Cardioform Septal Occluder |
| Impulse Dynamics (USA) INC. | $48.82 | 2024 | Optimizer |
| Chiesi USA, INC. | $47.59 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $43.01 | 2022-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $42.67 | 2022-2025 | |
| Irhythm Technologies, INC. | $41.41 | 2022-2024 | Zio Xt Patch, Zio Monitor |
| Heartflow, INC. | $33.67 | 2023 | Ffrct |
| Biosense Webster, INC. | $33.65 | 2023 | Na |
| Alnylam Pharmaceuticals INC. | $32.73 | 2023-2024 | Onpattro |
| Lexicon Pharmaceuticals, INC. | $25.78 | 2024 | |
| Novo Nordisk INC | $20.66 | 2025 | Wegovy |
| Amarin Pharma, INC. | $19.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abhishek Sinha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.